Navigation Links
Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
Date:5/22/2013

LAGUNA HILLS, Calif., May 22, 2013 /PRNewswire/ -- Advanced Prenatal Therapeutics (APT), a privately held company, is developing a medical device that will help alleviate the high blood pressure and other symptoms associated with preeclampsia. APT's targeted apheresis cartridge is expected to be the first medical device specifically designed to treat preeclampsia, a leading cause of maternal and fetal death.

Every year, preeclampsia affects approximately 300,000 pregnant women in the United States. It is characterized by high blood pressure and proteinuria induced by pregnancy. Treatment currently consists of bed rest and other supportive measures such as closely monitoring the patient. To avoid the life-threatening complications of preeclampsia, the baby is often delivered prematurely at the first signs of distress. Unfortunately, premature delivery is also a primary cause of infant death and life-long disabilities.

APT's patent-pending technology uses a process called "targeted apheresis" to remove harmful proteins that are involved in the disease process from the mother's blood while preserving the blood components that are healthy and viable. In preeclampsia, the placenta produces harmful proteins that prevent the action of certain growth factors that regulate blood vessel growth. These harmful proteins are believed to contribute to maternal high blood pressure and other symptoms of preeclampsia. Removal of these harmful proteins using targeted apheresis could alleviate maternal high blood pressure and other symptoms of preeclampsia. It could also help extend the duration of the pregnancy – and perhaps even lead to healthy babies born on time.

Apheresis is a common procedure similar to kidney dialysis in which the patient's blood is passed through a device that separates and removes a particular substance from the blood and returns the cleaned blood back to the patient. "Preeclampsia is a completely unmet medical need," explains Dr. James Smith , President and CEO of APT. "We are extremely proud to be developing what we expect to be a very viable and low-risk therapy for preeclampsia."

About Advanced Prenatal Therapeutics, Inc. (www.advancedprenatal.com) Advanced Prenatal Therapeutics, Inc.'s mission is to develop treatments for preeclampsia that will safely prolong pregnancy. To accomplish this goal, APT is developing a novel therapeutic device for preeclampsia that specifically removes harmful factors from the mother's blood. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed, or that the novel therapeutic products will receive regulatory clearance, or achieve commercial success.

Investor Relations:
Dan Thiel
949.340.7261
dthiel@advancedprenatal.com


'/>"/>
SOURCE Advanced Prenatal Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
3. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
4. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
5. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
6. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. PeriGen, Inc. Introduces New, Advanced Perinatal System at National Perinatal Nursing Convention
9. Advanced Radiotherapy Techniques Explored at Educational Events in India
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... PROSHRED franchises from across the country gathered at the La Valencia Hotel in ... performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking away ...
(Date:2/5/2016)... ... 05, 2016 , ... Give To Cure today announced that it ... to Give To Cure’s campaign that is crowdfunding clinical trials to help find cures ... payments through a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):